ALX Oncology (ALXO) News Today $1.74 +0.11 (+6.75%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period ALX Oncology launches new equity incentive planJanuary 18 at 8:31 PM | msn.comALX Oncology Adopts 2025 Inducement Equity PlanJanuary 17, 2025 | tipranks.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest UpdateALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) saw a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 7,600,000 shares, a drop of 9.4% from the December 15th total of 8,390,000 shares. Based on an average trading volume of 984,300 shares, the days-to-cover ratio is currently 7.7 days. Currently, 24.6% of the shares of the company are sold short.January 17, 2025 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by BrokeragesALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six ratings firms that are currently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have assigned aJanuary 17, 2025 | marketbeat.comALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | finance.yahoo.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 10,796 SharesALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) insider Jaume Pons sold 10,796 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $1.58, for a total value of $17,057.68. Following the completion of the sale, the insider now directly owns 580,714 shares of the company's stock, valued at $917,528.12. The trade was a 1.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.January 2, 2025 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Large Increase in Short InterestALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 8,390,000 shares, a growth of 17.0% from the November 30th total of 7,170,000 shares. Currently, 24.4% of the shares of the company are sold short. Based on an average trading volume of 937,300 shares, the short-interest ratio is currently 9.0 days.December 29, 2024 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from AnalystsALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has received an average recommendation of "Moderate Buy" from the six analysts that are currently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have given aDecember 23, 2024 | marketbeat.comALX Oncology falls as Jefferies cuts on lead cancer drugDecember 20, 2024 | msn.comJefferies Downgrades ALX Oncology Holdings (ALXO)December 20, 2024 | msn.comAlx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold'December 19, 2024 | msn.comJefferies Financial Group Downgrades ALX Oncology (NASDAQ:ALXO) to HoldJefferies Financial Group lowered ALX Oncology from a "buy" rating to a "hold" rating and reduced their target price for the company from $12.00 to $2.00 in a report on Thursday.December 19, 2024 | marketbeat.comALX Oncology to present updated results from Phase 2 ASPEN-06 trialDecember 18, 2024 | markets.businessinsider.comALX Oncology (NASDAQ:ALXO) Earns "Overweight" Rating from Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of ALX Oncology in a report on Wednesday.December 18, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for ALX Oncology (NASDAQ:ALXO)HC Wainwright restated a "buy" rating and set a $25.00 price objective on shares of ALX Oncology in a research report on Wednesday.December 18, 2024 | marketbeat.comALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers SymposiumDecember 18, 2024 | globenewswire.comALX Oncology Holdings (ALXO) Gets a Hold from LifeSci CapitalDecember 18, 2024 | markets.businessinsider.comALX Oncology to host virtual event to discuss Phase 1b/2 evorpacept dataDecember 12, 2024 | markets.businessinsider.comALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024December 12, 2024 | markets.businessinsider.comFmr LLC Sells 1,949,890 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO)Fmr LLC cut its position in ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) by 25.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,865,106 shares of the company's stock after selling 1,9December 12, 2024 | marketbeat.comInsider Buying: ALX Oncology Holdings Inc. (NASDAQ:ALXO) Director Purchases 30,000 Shares of StockDecember 5, 2024 | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have assignedNovember 28, 2024 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six research firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have given aNovember 28, 2024 | marketbeat.comALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | markets.businessinsider.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Significant Decrease in Short InterestALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) was the recipient of a large decrease in short interest in October. As of October 31st, there was short interest totalling 7,840,000 shares, a decrease of 18.2% from the October 15th total of 9,590,000 shares. Currently, 25.9% of the shares of the stock are sold short. Based on an average daily volume of 701,400 shares, the days-to-cover ratio is presently 11.2 days.November 15, 2024 | marketbeat.comCantor Fitzgerald Comments on ALX Oncology FY2024 EarningsALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) - Stock analysts at Cantor Fitzgerald raised their FY2024 earnings per share estimates for ALX Oncology in a report released on Tuesday, November 12th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings perNovember 15, 2024 | marketbeat.comALX Oncology appoints Alan Sandler as CMONovember 15, 2024 | markets.businessinsider.comALX Oncology Strengthens Leadership with Key AppointmentNovember 15, 2024 | markets.businessinsider.comALX Oncology Appoints Alan Sandler, M.D., as Chief Medical OfficerNovember 14, 2024 | globenewswire.comALX Oncology Holdings: Hold Rating Amid Uncertainties and Upcoming CatalystsNovember 12, 2024 | markets.businessinsider.comCantor Fitzgerald Reiterates Overweight Rating for ALX Oncology (NASDAQ:ALXO)Cantor Fitzgerald reissued an "overweight" rating on shares of ALX Oncology in a research report on Tuesday.November 12, 2024 | marketbeat.comAnalysts Offer Predictions for ALX Oncology FY2028 EarningsALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) - Research analysts at HC Wainwright lowered their FY2028 earnings estimates for ALX Oncology in a report released on Friday, November 8th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $1.43 per share for the yeNovember 11, 2024 | marketbeat.comALX Oncology reports Q3 EPS (58c) consensus (78c)November 7, 2024 | markets.businessinsider.comALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | globenewswire.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by AnalystsALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommeNovember 3, 2024 | marketbeat.comALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024November 1, 2024 | globenewswire.comShort Interest in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Declines By 6.7%ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totalling 9,320,000 shares, a decline of 6.7% from the September 15th total of 9,990,000 shares. Approximately 30.9% of the company's stock are short sold. Based on an average daily trading volume, of 1,150,000 shares, the short-interest ratio is presently 8.1 days.October 16, 2024 | marketbeat.comAurora lightshow continues into the weekend across CanadaOctober 11, 2024 | ca.news.yahoo.comMillennium Management LLC Reduces Stake in ALX Oncology Holdings IncOctober 11, 2024 | finance.yahoo.comALX Oncology Holdings (NASDAQ:ALXO) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comALX Oncology Chief Medical Officer Sophia Randolph Resigns >ALXOOctober 4, 2024 | marketwatch.comPoint72 Asset Management L.P. Makes New $1.83 Million Investment in ALX Oncology Holdings Inc. (NASDAQ:ALXO)Point72 Asset Management L.P. acquired a new position in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 304,100 shares of the company's stock, valued at approximately $1,834,000. Point72 AssetOctober 4, 2024 | marketbeat.comMarshall Wace LLP Has $3.83 Million Stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO)Marshall Wace LLP increased its stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) by 423.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 635,679 shares of the company's stock after acquirinOctober 3, 2024 | marketbeat.comInvestors Balance Rate Elation Against Economic WorriesSeptember 21, 2024 | seekingalpha.comALX Oncology's Evorpacept Gains Momentum With FDA Fast Track DesignationsSeptember 12, 2024 | seekingalpha.comALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare ConferenceSeptember 9, 2024 | finance.yahoo.comALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with SanofiSeptember 4, 2024 | finance.yahoo.com396,966 Shares in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Acquired by Privium Fund Management B.V.Privium Fund Management B.V. bought a new position in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 396,966 shares of the company's stock,September 1, 2024 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from AnalystsShares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have aAugust 20, 2024 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Significant Growth in Short InterestALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 9,080,000 shares, an increase of 17.2% from the July 15th total of 7,750,000 shares. Based on an average daily volume of 1,280,000 shares, the days-to-cover ratio is presently 7.1 days. Approximately 30.5% of the company's shares are short sold.August 17, 2024 | marketbeat.com Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address ALXO Media Mentions By Week ALXO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALXO News Sentiment▼1.030.46▲Average Medical News Sentiment ALXO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALXO Articles This Week▼43▲ALXO Articles Average Week Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies REGENXBIO News Today Alumis News Today Compass Therapeutics News Today Valneva News Today Monte Rosa Therapeutics News Today Korro Bio News Today Neumora Therapeutics News Today MBX Biosciences News Today Precigen News Today Olema Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALXO) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.